Xilio Therapeutics (XLO) Other Non-Current Assets (2020 - 2026)

Xilio Therapeutics (XLO) has 7 years of Other Non-Current Assets data on file, last reported at $1.8 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Assets rose 1.4% year-over-year to $1.8 million; the trailing twelve-month figure through Mar 2026 stood at $1.8 million (up 1.4% YoY), and the FY2025 full-year result was $1.8 million, up 1.4% from the prior year.
• Other Non-Current Assets was little changed at $1.8 million in Q1 2026, from $1.8 million in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $2.8 million in Q1 2024 to a low of $92000.0 in Q2 2024.
• A 5-year average of $1.3 million and a median of $1.6 million in 2023 frame the typical range for Other Non-Current Assets.
• Across the five-year window, Other Non-Current Assets tumbled 89.15% in 2023 and soared 1850.0% in 2025, its largest moves.
• Tracing XLO's Other Non-Current Assets over 5 years: stood at $267000.0 in 2022, then tumbled by 45.69% to $145000.0 in 2023, then soared by 1128.97% to $1.8 million in 2024, then gained by 1.4% to $1.8 million in 2025, then climbed by 0.33% to $1.8 million in 2026.
• Business Quant data shows XLO's Other Non-Current Assets at $1.8 million in Q1 2026, $1.8 million in Q4 2025, and $1.8 million in Q3 2025.